This article was released as Pharm Edaily Premium Content on February 4, 2026, at 8:00 AM.


[NA Eun-kyung, Edaily Reporter] KOSPI and KOSDAQ rebounded on Tuesday, just one day after a so called wash shock, pushing the total market capitalization of South Korean equities above 5,000 trillion won.
T 황금성게임랜드 he pharmaceutical biotech and healthcare sector however underperformed the broader market. Among the top 20 gainers on the KOSDAQ only two companies were classified as pharmaceutical biotech or health 오리지널바다이야기 care firms Celemics and Mediana.



Celemics’ target capture kit for NGS-based genetic analysis (Source: Celemics)


Celemics 바다이야기사이트 jumps ahead of late disclosure on ownership change
According to KG Zeroin MP Doctor, formerly Market Point, next generation sequencing based genetic analysis company Celemics saw its shares 바다이야기고래 surge to the daily upper limit on the day.
The rally drew attention from investors, as there had been no market disclosed positive developments over the past week. The company’s most recent 황금성오락실 disclosure prior to Tuesday was a single supply contract announcement dated Dec. 24 of last year.
Later that evening, Celemics released what is commonly referred to as an owl disclosure, meaning an announcement made after market hours when investor attention is typically lower. The company disclosed a change in its largest shareholder along with a 4.3 billion won third party allotment capital increase.
Under a share purchase agreement, co CEOs Lee Yong hoon and Kim Hyo gi, the latter previously the largest shareholder, will transfer about 430,000 shares, or 5.27 percent of outstanding shares, to Park Jong gap at 6,000 won per share. The total transaction value amounts to 2.6 billion won.
Park had previously owned a 0.7 percent stake in Celemics. Following the transaction, he will hold a 5.97 percent stake, becoming the company’s largest shareholder.
Park and Sun Ki jong are named as participants in the third party allotment, receiving 760,746 shares and 491,710 shares, respectively. Celemics said the capital increase was decided to secure funds for management purposes, including business diversification.
The company also plans to issue 5 billion won worth of convertible bonds at the same time. Of the proceeds, 1 billion won will be used for workforce expansion and market development while 400 million won will be allocated to intangible asset acquisitions and overseas subsidiary operations.
Changes in controlling shareholders, capital increases and convertible bond issuance are typically considered price sensitive events. Market participants are closely watching whether these factors were already priced into the stock’s sharp rise.
Celemics posted 6.7 billion won in revenue and an operating loss of 1.9 billion won in 2024. Its main revenue source is target capture kits, which selectively extract specific regions of the genome to enable efficient genetic testing.
The company says the technology allows detection of COVID 19 variants using minimal samples and can also be customized for cancer and other infectious diseases.
Celemics set its initial public offering price at the top of the indicative range, 20,000 won, after strong investor demand in 2020. Since then, the stock has steadily declined and has not exceeded its IPO price since 2022.
Even after hitting the daily upper limit, Tuesday’s closing price stood at 3,870 won just 19.3 percent of the IPO price. Edaily made several attempts to contact Celemics for comment on the stock’s movement but received no response.
Mediana rallies on strong earnings
Shares of Mediana, an affiliate of SELVAS AI rose 21.9 percent from the previous session to close at 25,600 won.
The company disclosed the previous day that its consolidated revenue reached 64.8 billion won, with operating profit of 5.7 billion won, marking a 339 percent year on year increase.
The sharp improvement in earnings appears to have driven the stock’s rally.
A Mediana official said sales surged in its vascular access device segment, the company’s core business, and internalizing manufacturing technologies helped improve profitability. The official added that restructuring its distributor system and increased sales of automated external defibrillators also contributed.
Investor expectations are also rising for new businesses that are set to gain momentum this year. Just 10 trading days after launching its product, Mediana secured its first domestic supply contract for a wearable real time electrocardiogram monitoring solution with Medifield Hangang Hospital last month.
The company plans to integrate patient monitoring systems that were previously scattered across multiple devices, aiming to improve convenience for medical staff.
A Mediana official said the company will provide services that integrate wired and wireless monitoring solutions, various medical artificial intelligence technologies and multiple medical devices, enabling healthcare professionals to efficiently recognize alarms and respond to patient conditions.
Eubiologics hits 52 week high
Eubiologics extended its rally for a second straight day following the disclosure of record earnings on Monday.
Shares of the vaccine maker closed Tuesday up 10.6 percent at 13,820 won. The stock rose as high as 15,940 won during the session, marking a new 52 week high.
An Eubiologics official said the stock gain appears to reflect strong annual earnings.
Eubiologics generates more than 90 percent of its revenue from cholera vaccines and has renewed record earnings each year over the past three years while effectively monopolizing the public sector cholera vaccine market. The exclusive position is expected to continue through this year.
Recent gains are also interpreted as the market downplaying concerns over the United States’ formal withdrawal from the World Health Organization as a major negative factor for the company.
When former US President Donald Trump first announced plans to withdraw from the WHO last year, Eubiologics explained that cholera vaccines are purchased not through the WHO’s budget but through international aid organizations centered around Gavi, the Vaccine Alliance.
Demand from UNICEF for cholera vaccines is reported to have remained largely unchanged. An Eubiologics official said this year’s supply volume to UNICEF is expected to be similar to the amount supplied in 2025.
나은경 (eeee@edaily.co.kr)